This hypothesis is supported by the observation that individuals receiving adenovirus-based vector vaccines had lower anti-spike IgA levels, which correlated with a higher prevalence of COVID-19 after vaccination compared to those individuals who received the BNT162b2 vaccine (18.7% vs. 2.6%, Table S1). Here, CD79A is linked to COVID-19.